- Home
- ELUT vs ALGS Comparison
ELUT vs ALGS Comparison
Compare ELUT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELUT | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 34.6M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELUT | ALGS |
|---|---|---|
| Price | $0.85 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $36.88 |
| AVG Volume (30 Days) | ★ 73.7K | 37.4K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,293,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | $1,433.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $3.98 |
| 52 Week High | $1.39 | $13.69 |
Technical Indicators
Market Signals| Indicator | ELUT | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 33.97 |
| Support Level | $0.75 | N/A |
| Resistance Level | $0.87 | $6.91 |
| Average True Range (ATR) | 0.07 | 0.42 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 74.04 | 5.09 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.